ストックスクリーナーアプリを入手
64.49
1.39%
-0.91
Halozyme Therapeutics Inc (HALO) 最新ニュース
How The Investment Story Is Shifting For Halozyme Therapeutics (HALO) After Recent Analyst Calls - Yahoo Finance
Hedge Fund and Insider Trading News: Warren Buffett, George Soros, Steve Cohen, Ken Griffin, Brevan Howard, Tudor Investment Corp, L.B. Foster (FSTR), Halozyme Therapeutics Inc (HALO), and More - Insider Monkey
Halozyme Therapeutics (HALO) appoints interim CFO amid growth plans - MSN
Tema Etfs LLC Invests $1.7M in Halozyme Therapeutics - National Today
Tema Etfs LLC Makes New $1.70 Million Investment in Halozyme Therapeutics, Inc. $HALO - marketbeat.com
Halozyme Therapeutics CEO sells $2.59 million in stock By Investing.com - Investing.com Canada
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock - MarketBeat
Halozyme (NASDAQ: HALO) grants 10,000 RSUs to interim CFO Ramsay - Stock Titan
Halozyme (NASDAQ: HALO) CEO exercises 40k options, sells 40k shares - Stock Titan
HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
HALOZYME THERAPEUTICS Accounts Payable & Accrued Expense: $1 - GuruFocus
Is Halozyme Therapeutics (HALO) Pricing Reflect Its Potential After Recent Share Price Pullback - Sahm
Halozyme Therapeutics Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth Plans - Insider Monkey
Halozyme to Report Second Quarter 2025 Financial and Operating Results - Quantisnow
Record revenue and royalties fail to lift Halozyme Therapeutics stock amid sustained technical weakness - Traders Union
Sell Signal: Will Halozyme Therapeutics Inc announce a stock split2026 Sentiment & Proven Capital Preservation Methods - baoquankhu1.vn
Assenagon Asset Management Acquires Stake in Halozyme Therapeutics - National Today
Assenagon Asset Management S.A. Takes Position in Halozyme Therapeutics, Inc. $HALO - marketbeat.com
Halozyme (HALO) loses 9% on weak earnings - MSN
Halozyme Therapeutics Inc Stock Historical Valuations | HAM:RV7 - GuruFocus
Halozyme Therapeutics Inc Stock Intrinsic Values - GuruFocus
5 Most Undervalued Growth Stocks to Buy According to Analysts - Insider Monkey
HALO (Halozyme Therapeutics) Cash Receipts from Loans - GuruFocus
Why is Halozyme Therapeutics (HALO) down 13.1% since last earnings report? - MSN
HALO (Halozyme Therapeutics) Cash Receipts from Tax Refunds - GuruFocus
Halozyme Therapeutics prices $1.3 billion convertible notes - MSN
Vanguard realignment reports zero Halozyme holdings (NASDAQ: HALO) - Stock Titan
A Look At Halozyme Therapeutics (HALO) Valuation After Mixed Quarterly Earnings And Guidance - Sahm
Is Halozyme’s Interim CFO Appointment Shaping The ENHANZE Royalty Story For Halozyme Therapeutics (HALO)? - simplywall.st
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks - Yahoo Finance
Halozyme declines after Q4 bottom line miss, reiterates 2026 guidance - MSN
Congress Asset Management Co. Cuts Stake in Halozyme Therapeutics - National Today
Congress Asset Management Co. Cuts Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Interim CFO at Halozyme (NASDAQ: HALO) files initial Form 3 ownership - Stock Titan
HALOZYME THERAPEUTICS, INC. ($HALO) President and CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] HALOZYME THERAPEUTICS, INC. SEC Filing - Stock Titan
Executive pay, board elections lead Halozyme (NASDAQ: HALO) 2026 proxy - Stock Titan
Halozyme appoints David Ramsay as interim CFO - MSN
Moving Averages: Will Halozyme Therapeutics Inc benefit from seasonality2026 Buyback Activity & Proven Capital Preservation Methods - baoquankhu1.vn
Halozyme Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics - Markets Mojo
Halozyme Therapeutics, Inc. $HALO Shares Purchased by Allworth Financial LP - MarketBeat
Halozyme Touts $1.8B Revenue Outlook, Expanding Subcutaneous Drug Delivery - National Today
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026 - GlobeNewswire Inc.
What Has Caused Halozyme Therapeutics (HALO) Shares to Fall 13.1% Following Its Most Recent Earnings Report? - Bitget
Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report? - Yahoo Finance
Halozyme Therapeutics : ESG Key Data & Metrics (rev11 Halozyme ESG Key Data 2026 ISS Corporate comments Mar2026 version 1 for publication) - marketscreener.com
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference - MarketBeat
Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target - MSN
Alliancebernstein Reduces Stake in Halozyme Therapeutics - National Today
Alliancebernstein L.P. Trims Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Could Halozyme (HALO) Returning David Ramsay as Interim CFO Reframe Its ENHANZE Royalty Story? - simplywall.st
Growth Value: Is Halozyme Therapeutics Inc forming a bullish divergenceWeekly Trend Summary & Low Risk High Reward Trade Ideas - baoquankhu1.vn
0.49%
1.47%
大文字化:
|
ボリューム (24 時間):